Hologic — Merger or Acquisition (May 2012)
22 slides from Hologic's merger presentation, May 1, 2012
Slide 1: Creating a Leading Diagnostics Franchise Focused on Women's Health
Creating a Leading Diagnostics Franchise Focused on Women’s Health April 30, 2012 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking information that involves risks and uncertainties, including statements about Hologic’s and Gen-Probe’s plans, objectives, expectations and intentions. Such statements include, without limitation, statements about the timing of th
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures Hologic, Inc. (the “Company”) has presented the following non-GAAP financial measures in this presentation : adjusted net income and adjusted EBITDA of each of Hologic and Gen-Probe, and pro forma adjusted net income, adjusted EPS and adjusted EBITDA of the combine
Slide 4: Transaction Summary
Transaction Summary Agenda Strategic Rationale Financial Highlights Roadmap to Completion
Slide 5: Combination of Leading Diagnostics Franchises
Combination of Leading Diagnostics Franchises Combines Best-in-Class Technologies Strengthens Molecular Diagnostics Franchise Comprehensive Cervical Cancer Screening Solution Complementary Sales Force and Product Offering Opportunity to Accelerate International Expansion Strong Growth and Margin Pro
Slide 6: Transaction Summary
Structure Considerations Approvals Closing Transaction Summary Hologic will acquire all of the outstanding shares of Gen-Probe for $82.75 per share for total enterprise value of $3.7 billion 100% cash transaction funded through available cash and additional financing of term loans and high yield sec
Slide 7: Strategic Rationale
Strategic Rationale Agenda Transaction Summary Financial Highlights Roadmap to Completion
Slide 8: Hologic's Best-in-Class Technologies; Gen-Probe's Complementary Products
Breast Health Surgical Diagnostics Hologic’s Best-in-Class Technologies Gen-Probe’s Products Are Highly Complementary Complementary technologies & markets… …with a focus on R&D to drive future growth
Slide 9: Leading Cervical Cancer Screening Solutions
Class Leading Cervical Cancer Screening Solutions Flexible Depending on Market Need Type of Lab Combined Cervical Cancer Screening Offerings: APTIMA Cervista Genotyping TPPT & Imaging
Slide 10: Combined Menu & Sales Force Infrastructures
• Drive Test Utilization • Drive Compliance • Communicate Guidelines • Portfolio Sales Combined Menu & Sales Force Infrastructures Combined Company Menu • HPV - APTIMA - Cervista - Genotyping • CT / NG • Trichomonas • TPPT & Imaging • fFn Combined Sales Call Point • Molecular Lab • Cytology Lab • Ph
Slide 11: International Expansion
International Expansion: Combining Hologic’s Worldwide Direct Sales Force & Distribution Partners with Gen-Probe’s Assays & Platforms • Use Hologic’s International Direct Sales Force to Accelerate Global Adoption of Gen-Probe’s Automation & Assays • Further Round Out Hologic’s International Portfoli
Slide 12: Financial Highlights
Financial Highlights Agenda Transaction Summary Strategic Rationale Roadmap to Completion
Slide 13: Poised to Create Significant Long-Term Shareholder Value
Poised to Create Significant Long-Term Shareholder Value Financial Highlights Strong Financial Profile and Immediate EPS Accretion Accelerates Top and Bottom-Line Growth Diversified Revenue Mix in Women’s Health Significant Synergies Disciplined Balance Sheet Approach Poised to Create Significant Lo
Slide 14: Estimated to be $0.20 Accretive to Adjusted EPS For First Full Year After Close
Estimated to be $0.20 Accretive to Adjusted EPS For First Full Year After Close Strong Financial Profile and Immediate EPS Accretion LTM as of 31-Mar-2012 Revenue ($mm) $1,862 $587 Adjusted EBITDA ($mm) $634 $188 % Margins 34% 32% Pro Forma $2,449 $822 34%
Slide 15: Combination Poised for Sustained Growth
Combination Poised for Sustained Growth Gen-Probe’s Consistent Track Record of Growth Accelerates Top and Bottom-Line Growth Combination Poised for Sustained Growth Strength of Current Growth Portfolio (Tomo, Myosure, CT/NG, HPV, Trich) International Infrastructure Provides Expansion Opportunity Inc
Slide 16: 86% Women's Health Focus
86% Women’s Health Focus Diversified Revenue Mix In Women’s Health 17% Surgical 5% Skeletal 46% Breast Health 32% Diagnostics 61% Diagnostics 35% Blood Screening 4% Other 50% Diagnostics ($1.2bn) 38% Women’s Imaging ($0.9bn) 12% Surgical ($0.3bn)
Slide 17: $40 Million in Cost Synergies Anticipated in Year One
$40 Million in Cost Synergies Anticipated in Year One Significant Synergies $75 million of projected annual cost savings within 3 years Cross-selling provides potential for meaningful revenue synergies — Alignment of assets to maximize efficiencies — Overhead consolidation $40 Million in Cost Synerg
Slide 18: Disciplined Balance Sheet Approach
Disciplined Balance Sheet Approach Pro forma LTM net leverage of 5.3x * expected to be below 5.0x by fiscal year- end Robust cash flow expected to provide ability to return to pre-transaction leverage level within 3 years Operating Cash Flow (LTM, March 31, 2012) Pro Forma * Including synergies $ 45
Slide 19: Roadmap to Completion
Roadmap to Completion Agenda Transaction Summary Strategic Rationale Financial Highlights
Slide 20: Management Team Focused on Seamless Integration
Management Team Focused on Seamless Integration Roadmap to Completion Integration teams to report to CEOs Intention to retain Gen-Probe senior management team and San Diego presence Well-recognized Gen-Probe brand will be maintained Regulatory authorities approvals Gen-Probe shareholder vote Expecte
Slide 21: Combination of Leading Diagnostics Franchises
Combination of Leading Diagnostics Franchises Combines Best-in-Class Technologies Strengthens Molecular Diagnostics Franchise Comprehensive Cervical Cancer Screening Solution Complementary Sales Force and Product Offering Opportunity to Accelerate International Expansion Strong Growth and Margin Pro
Slide 22: Reconciliation of GAAP Net Income to Non-GAAP
Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income and Pro Forma EBITDA Hologic Gen-Probe Twelve Months ended March 24, 2012 Twelve Months ended March 31, 2012 Pro Forma Combined NET INCOME GAAP net income 44,304 $ 49,307 $ 93,611 $ Adjustments: Amortization of intangible assets 242,1